ANTIBODIES TO ETANERCEPT AND ADALIMUMAB IN RHEUMATOID ARTHRITIS INADEQUATE RESPONDERS AND CLINICAL OUTCOMES AFTER AN ACTIVE SWITCH TO INFLIXIMAB

被引：0
|
作者：
Pool, C. [1 ]
Shankar, G. [2 ]
Schantz, A. [2 ]
Gunn, G. [2 ]
Bolce, R. [1 ]
Leirisalo-Repo, M. [3 ]
Wang, J. [2 ]
Goldman, J.
DeHoratius, R. [1 ]
Fleischmann, R. [4 ]
Decktor, D. [1 ]
机构：
[1] Janssen Serv LLC, Horsham, PA USA
[2] Janssen R&D LLC, Spring House, PA USA
[3] Helsinki U Cent Hosp, Helsinki, Finland
[4] Metroplex Clin Res Ctr, Dallas, TX USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：224 / 225
页数：2
相关论文
共 50 条
  • [31] The 6-month change in disease activity and disability after treatment with adalimumab compared to etanercept and infliximab in patients with rheumatoid arthritis in daily clinical practice
    Kievit, W.
    Fransen, J.
    Brus, H. C.
    De Gendt, C. M.
    Jansen, T. L.
    Janson, M.
    Kupper, H. H.
    Moolenburgh, J. D.
    Van Oijen, P. L. M.
    D'Amelio, R.
    Ronday, K. H.
    De Rooij, D. J. R. A.
    Adang, E. E.
    Van Riel, P. L. C. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 325 - 325
  • [32] Efficacy and safety of adalimumab (HUMIRA®) in 899 patients with rheumatoid arthritis (RA) who previously failed etanercept and/or infliximab in clinical practice
    Bombardieri, S.
    McKenna, F.
    Drosos, A. A.
    Michel, B. A.
    Hartz, D.
    Oezer, U.
    Kupper, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 178 - 178
  • [33] Clinical and economic efficiency to reduce dose etanercept and adalimumab in patients with rheumatoid arthritis
    Rosalía Martínez-Pérez
    Sergio Rodríguez-Montero
    Alejandro Muñoz
    Julia Uceda
    Mario León
    Francisco Gallo
    Maria Luisa Velloso
    José Luis Marenco
    Journal of Translational Medicine, 10 (Suppl 3)
  • [34] ETANAR - A ETANERCEPT BIOSIMILAR IS AS EFFECTIVE AS ADALIMUMAB AND INFLIXIMAB IN A COHORT OF REAL-LIFE OF PATIENTS WITH RHEUMATOID ARTHRITIS
    Santos-Moreno, P.
    Saavedra-Martinez, G.
    Villarreal, L.
    Gomez, D.
    Bello-Gualtero, J.
    Giraldo, V.
    Martinez, P.
    Sanchez, A.
    Sanchez, M.
    Uribe, E.
    Boon, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 789 - 790
  • [35] Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
    Radstake, T. R. D. J.
    Svenson, M.
    Eijsbouts, A. M.
    van den Hoogen, F. H. J.
    Enevold, C.
    van Riel, P. L. C. M.
    Bendtzen, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (11) : 1739 - 1745
  • [36] Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis
    Doan, Quan V.
    Chiou, Chiun-Fang
    Dubois, Robert W.
    JOURNAL OF MANAGED CARE PHARMACY, 2006, 12 (07): : 555 - 569
  • [37] Comparison of the efficacy of the tumour necrosis factor α blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis
    Hochberg, MC
    Tracy, JK
    Hawkins-Holt, M
    Flores, RH
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 13 - 16
  • [38] COMPARISON OF HEALTHCARE COSTS BETWEEN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH INFLIXIMAB, ETANERCEPT AND ADALIMUMAB IN NORDIC SETTING
    Gokhale, S. B.
    Cassel, T.
    Mahon, R.
    Balkin, P. E.
    Singh, S.
    Bhattacharyya, S.
    Handin, J.
    Mendoza, C.
    VALUE IN HEALTH, 2016, 19 (07) : A535 - A535
  • [39] Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study
    Schabert, V. F.
    Bruce, B.
    Ferrufino, C. F.
    Globe, D. R.
    Harrison, D. J.
    Lingala, B.
    Fries, J. F.
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (04) : 569 - 580
  • [40] Etanercept -: infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFα
    Brocq, O
    Plubel, Y
    Breuil, V
    Grisot, C
    Flory, P
    Mousnier, A
    Euller-Ziegler, L
    PRESSE MEDICALE, 2002, 31 (39): : 1836 - 1839
12345